Pre-made Lorigerlimab benchmark antibody ( Whole mAb, anti-PDCD1/PD-1;CTLA4/CTLA-4 therapeutic antibody, Anti-CD279,PD1/SLEB2/hPD-1/hPD-l/hSLE1;CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Lorigerlimab biosimilar, Whole mAb, Anti-PDCD1/PD-1;CTLA4/CTLA-4 Antibody: Anti-CD279/PD1/SLEB2/hPD-1/hPD-l/hSLE1;CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-679-1mg	1mg	Inquiry
GMP-Bios-ab-679-10mg	10mg	Inquiry
GMP-Bios-ab-679-100mg	100mg	Inquiry
GMP-Bios-ab-679-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Lorigerlimab biosimilar, Whole mAb, Anti-PDCD1/PD-1;CTLA4/CTLA-4 Antibody: Anti-CD279/PD1/SLEB2/hPD-1/hPD-l/hSLE1;CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody
INN Name	Lorigerlimab
Target	PD-1;CTLA-4
Format	Bispecific Mixed scFv (scFv-CH2-CH3-scFv)
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG4;IgG4
VD LC	Kappa;Kappa
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Active
100% SI Structure	None;None
99% SI Structure	None;None
95-98% SI Structure	None;5xj3:AB/5tru:HL/6jc2:HL/6rp8:hl/7erx:HL
Year Proposed	2021
Year Recommended	na
Companies	MacroGenics
Conditions Approved	na
Conditions Active	Solid tumours
Conditions Discontinued	na
Development Tech	Dual-Affinity Re-Targeting Technology